Physician profile
Samer Ali
NPI 1467500223
$642.43
in general payments reported to CMS, 2019-2025
12 companies · $272 in 2025
The $272 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54.38 · 2020: $16.67 · 2021: $48.66 · 2022: $65.05 · 2023: $34.36 · 2024: $151 · 2025: $272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $458.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $457.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $134.86 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $90.04 | 2025 | Verquvo, Zerbaxa |
| Gilead Sciences, INC. | $81.98 | 2022-2023 | Veklury |
| Mallinckrodt Hospital Products INC. | $76.05 | 2024-2025 | Terlivaz |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $67.41 | 2024-2025 | Lifevest |
| Stryker Corporation | $40.24 | 2025 | Flowtriever |
| Pfizer INC. | $33.67 | 2021 | |
| Cvrx, INC. | $31.74 | 2025 | Barostim Neo System |
| Viatris Specialty LLC | $27.10 | 2025 | Yupelri |
| Mylan Specialty L.P. | $24.38 | 2024 | Yupelri |
| Amgen INC. | $17.53 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $17.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samer Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.